With the development of genomics and cancer detection technologies, companies like Illumina and Grail have shown promising growth potential. This article explores investment opportunities in these emerging fields centered around the key word “how to invest in grail”.
Illumina’s acquisition of Grail opens up investment possibilities
Illumina, known as the “Google of genomics”, acquired cancer detection pioneer Grail for $7 billion. This consolidates Illumina’s leading position in gene sequencing and expands its footprint in the potentially lucrative liquid biopsy market. Investors can gain exposure through Illumina stock. The global cancer gene sequencing market is estimated to reach $75 billion by 2035.
Investing in startups catching up to Grail
Despite antitrust concerns, Illumina’s CEO argues the Grail acquisition will stimulate competition by attracting funding to startups working on early cancer detection. Investors can identify and invest in promising startups in this space, like Delfi Diagnostics, Faraday Pharmaceuticals and TailorMed.
Betting on the growth of the genomics market
As the world’s largest gene sequencing company, Illumina is well-positioned to benefit from the expanding genomics market. Its gene sequencing tools power liquid biopsy tests that have the potential to profoundly impact cancer care. Investors bullish on genomics can consider adding Illumina stock to their portfolio.
The emerging genomics and liquid biopsy market offers exciting investment opportunities. By acquiring Grail, Illumina consolidates its leadership in gene sequencing while expanding into early cancer detection. Investors can gain exposure by investing in Illumina stock or identifying startups catching up to Grail.